Indications for BEVESPI AEROSPHERE:
Maintenance treatment of COPD, including chronic bronchitis and/or emphysema.
Limitations of Use:
Not indicated for relief of acute bronchospasm or for treatment of asthma.
2 inhalations twice daily (in the AM + PM). Max 2 inhalations twice daily.
Use of LABA without inhaled corticosteroid (ICS) in asthma.
LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in acute deteriorating COPD. Not for relief of acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Cardiovascular disorders (eg, coronary insufficiency, cardiac arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Hepatic disease; monitor. Severe renal impairment or ESRD requiring dialysis. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.
Anticholinergic + long-acting beta-2 agonist (LABA).
Caution with concomitant other adrenergic drugs; may potentiate sympathetic effects. Concomitant xanthine derivatives, steroids, or diuretics may potentiate hypokalemia. Caution with non-K+-sparing diuretics. Extreme caution with MAOIs, tricyclics, or others that prolong QTc interval. Antagonized by β-blockers; if needed, use cardioselective agents if no acceptable alternatives. Additive effects with concomitant other anticholinergic-containing drugs; avoid.
UTI, cough; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects.
Inhalation aerosol—10.7g (120 inh)